+

WO1994027578A1 - Gel a usage therapeutique in situ - Google Patents

Gel a usage therapeutique in situ Download PDF

Info

Publication number
WO1994027578A1
WO1994027578A1 PCT/SE1994/000522 SE9400522W WO9427578A1 WO 1994027578 A1 WO1994027578 A1 WO 1994027578A1 SE 9400522 W SE9400522 W SE 9400522W WO 9427578 A1 WO9427578 A1 WO 9427578A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
composition
solution
drug
mos
Prior art date
Application number
PCT/SE1994/000522
Other languages
English (en)
Inventor
Johan Carlfors
Katarina Edsman
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to AU69405/94A priority Critical patent/AU6940594A/en
Priority to JP7500555A priority patent/JPH08510731A/ja
Priority to EP94917868A priority patent/EP0706372A1/fr
Publication of WO1994027578A1 publication Critical patent/WO1994027578A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • the present invention is related to the field of slow release drug delivery systems for therapeutic use, especially in the ophthalmic field, and provides an aqueous liquid composition which in contact with a physiological solution forms a gel matrix which has been found to stay for a considerable time in the administration area, for instance the eye, without causing any problems to the patient.
  • This gel can be utilized for controlled continuous administration of drug over a prolonged period of time.
  • a composition according to the invention can be used in a number of situations, e.g. oral, buccal, nasal and vaginal administration, when a slow release system is advantageous but will in the following be discussed mainly in connection with it's ophthalmological use since the requirements here are especially high.
  • a solid implant containing the active drug is manufactured and delivered to the doctor or nurse for application onto the patient's conjunctiva, preferably under one of the eye lids.
  • These type of implants often have an outer membrane layer through which the drug is allowed to diffuse. The release rate depends on the membrane structure as well as the internal matrix in which the drug is incorporated.
  • compositions which at room temperature and below this value is liquid (non-solid) is instilled into the eye and due to the rise in temperature forms a polymer matrix, for instance a gel.
  • a polymer matrix for instance a gel.
  • Some systems have been disclosed which are physiologically acceptable and which form a gel in contact with a physiological salt solution, for instance a tear solution. It is readily appreciated that according to this concept potentially very useful systems for drug delivery are provided.
  • compositions of the type mentioned above in contrast to the teaching of the prior art are made hypotonic. Gels formed under these conditions have been found to stay considerably longer in the eye compared to gels formed at higher tonicity values, e.g. under isotonic conditions, hence providing a more efficient delivery system.
  • the invention is accordingly related to a liquid hypotonic ophthalmic solution comprising a pharmaceutically active drug and at least one hydrophilic polymer of the type which undergoes liquid-gel phase transition gelling in situ in contact with the physiological solution, for instance tear solution or humour solution when used for intraocular administration.
  • a method for administration of a drug is provided using a composition as defined in this specification.
  • the hydrophilic polymer is functionally defined by the ability of an aqueous solution of the polymer to form a solid polymer structure, for instance a gel, when the ionic strength is raised to physiological values.
  • components belonging to this group include polysaccharides and natural as well as synthetic polysaccharide derivatives.
  • the preferred component at present is an extracellular anionic heteropolysaccharide produced by the bacterium Pseudo onas elodea, known as gellan gum and marketed as GelriteTM.
  • the gel forming component may in more general terms be any component which before administration is a liquid but forms a gel upon contact with a physiological fluid due to exchange of components between said liquid and the physiological fluid.
  • Such exchange of components include but is not limited to proteins, such as lysozymes, and ionic components as discussed above.
  • concentration of the gel forming component in cases when Gelrite is used is preferably in the range of from 0.1 to 10 % by weight, especially 0.1-2 % by weight.
  • the non- solid composition containing the hydrophilic polymer solution is hypotonic. It has been found, however, that the tonicity should not be too low since this causes undesirable side- effects, such as more or less severe initial irritation when the composition is applied.
  • the osmolality of the non-solid composition should accordingly be lower than that of an isotonic solution (about 290 mOs/kg) and a selected range according to this invention is from about 25 - 200 mOs/kg, preferably 25-150 mOs/kg and especially 50-150 mOs/kg.
  • the at present most prefered composition has a value around 100 mOs/kg.
  • the drug component contained in the composition should preferably be present as a dispersive system, either as a suspension of particles or as an emulsion.
  • the drug could be incorporated in or associated with carrier substances in the form of particles e.g. polymers (biodegradable, non- biodegradable or polymers which dissolve or degrade upon contact with a physiological fluid) , lipids or ion-exchange resins.
  • EP424042 is disclosed a system based on compositions of the Gelrite type in which the drug is present in particles which dissolve due to change in pH when the composition is instilled into the eye.
  • the pH and the buffering capacity of the composition being such that the neutralizing action of lachrymal fluid is sufficient for dissolving the solid microparticles.
  • the drug component contained in the composition could also be present as a solution. It may be solubilized by surfactants, lipids or by complex-forming agents.
  • the active drug to be administered according to the present invention can be chosen among a great number of components, for instance for ophthalmological use.
  • examples of such components include
  • - antihistaminics and decongestants for instance pyrilamine, tetrahydrazoline, antazoline and analogues thereof,
  • - anti-inflammatories such as flubiprofen, diclofenac, acetylsalicylic acid, cortisone, hydrocortisone, dexamethasone, prednisone, indomethacin and analogues thereof
  • antibacterial substances such as tetracyclines, penicillin, bacitracin, sulphonamides and analogues thereof,
  • cytotoxics for instance 5-fluorouracil
  • - antiglaucoma drugs for instance prostaglandins like the omega chain modified derivatives disclosed in EP0364417 (esp. 13, 14-dihydro-17-phenyl-18, 19,20-trinor-PGF2 ⁇ -isopropylester) and timolol, pilocarpine, epinephrine, dipivalylepinephrine, and their analogues.
  • prostaglandins like the omega chain modified derivatives disclosed in EP0364417 (esp. 13, 14-dihydro-17-phenyl-18, 19,20-trinor-PGF2 ⁇ -isopropylester) and timolol, pilocarpine, epinephrine, dipivalylepinephrine, and their analogues.
  • composition may contain other additives such as polymers, preservatives, nonionic tonicity agents, solubilizers, buffer agents, complexing agents and chelating agents.
  • additives such as polymers, preservatives, nonionic tonicity agents, solubilizers, buffer agents, complexing agents and chelating agents.
  • the composition also contained a small amount of fluorescent particles. The time these particles were detectable in the instillation area was measured and taken as an indication of the effectiveness of the drug delivery system.
  • a glycerol concentration of 3% is close to an isotonic solution and represents a comparison with a prior art system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition d'apport d'un médicament pharmaceutique, et destinée notamment à un usage ophtalmologique, comprenant une solution hypotonique liquide d'au moins un polymère hydrophile du type subissant une gélification par transition de phase liquide-gel in situ au contact d'une solution physiologique, et un composé pharmaceutiquement actif, ainsi que son utilisation pour l'administration locale de médicaments.
PCT/SE1994/000522 1993-06-02 1994-06-01 Gel a usage therapeutique in situ WO1994027578A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU69405/94A AU6940594A (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use
JP7500555A JPH08510731A (ja) 1993-06-02 1994-06-01 治療使用のためのその場で生成するゲル
EP94917868A EP0706372A1 (fr) 1993-06-02 1994-06-01 Gel a usage therapeutique in situ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9301877A SE9301877D0 (sv) 1993-06-02 1993-06-02 In situ gel for therapeutic use
SE9301877-8 1993-06-02

Publications (1)

Publication Number Publication Date
WO1994027578A1 true WO1994027578A1 (fr) 1994-12-08

Family

ID=20390132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1994/000522 WO1994027578A1 (fr) 1993-06-02 1994-06-01 Gel a usage therapeutique in situ

Country Status (6)

Country Link
EP (1) EP0706372A1 (fr)
JP (1) JPH08510731A (fr)
AU (1) AU6940594A (fr)
CA (1) CA2164113A1 (fr)
SE (1) SE9301877D0 (fr)
WO (1) WO1994027578A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033562A1 (fr) * 1996-03-13 1997-09-18 Laboratoires Merck Sharp & Dohme-Chibret Snc Composition ophtalmologique subissant une transition de phase liquide/gel
FR2746014A1 (fr) * 1996-03-13 1997-09-19 Merck Sharp Dohme Chibret Lab Composition ophtalmologique du type subissant une transition de phase liquide-gel
FR2754712A1 (fr) * 1996-10-17 1998-04-24 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
WO1998023292A1 (fr) * 1996-11-29 1998-06-04 Monsanto Company Gel lubrifiant autonome (intact) utile pour apporter par voie orale des ingredients biologiquement actifs
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
US8216604B2 (en) 2003-01-10 2012-07-10 Archimedes Development Limited Method of managing or treating pain
CN109260146A (zh) * 2018-10-12 2019-01-25 广州大光制药有限公司 地夸磷索钠眼用即用型凝胶滴眼液及制备方法
US10485757B2 (en) 2015-01-27 2019-11-26 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US12005089B2 (en) 2014-12-15 2024-06-11 The Johns Hopkins University CVS transplantation for treatment of bacterial vaginosis

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004189731A (ja) * 2002-11-26 2004-07-08 Taisho Pharmaceut Co Ltd 点鼻剤
JP5304108B2 (ja) * 2007-08-30 2013-10-02 大正製薬株式会社 点眼剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227494A1 (fr) * 1985-10-03 1987-07-01 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Composition pharmaceutique du type subissant une transition de phase liquide-gel
EP0437368A1 (fr) * 1990-01-12 1991-07-17 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Composition ophthalmique lipide à base de microparticules lipidipes et contenant au moins un principe actif
EP0455396A1 (fr) * 1990-05-01 1991-11-06 MDV Technologies, Inc. Compositions de gel aqueux et leur utilisation
EP0495421A1 (fr) * 1991-01-15 1992-07-22 Alcon Laboratories, Inc. Utilisation de carragheenane dans des compositions ophthalmologiques topiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227494A1 (fr) * 1985-10-03 1987-07-01 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Composition pharmaceutique du type subissant une transition de phase liquide-gel
EP0437368A1 (fr) * 1990-01-12 1991-07-17 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Composition ophthalmique lipide à base de microparticules lipidipes et contenant au moins un principe actif
EP0455396A1 (fr) * 1990-05-01 1991-11-06 MDV Technologies, Inc. Compositions de gel aqueux et leur utilisation
EP0495421A1 (fr) * 1991-01-15 1992-07-22 Alcon Laboratories, Inc. Utilisation de carragheenane dans des compositions ophthalmologiques topiques

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033562A1 (fr) * 1996-03-13 1997-09-18 Laboratoires Merck Sharp & Dohme-Chibret Snc Composition ophtalmologique subissant une transition de phase liquide/gel
FR2746014A1 (fr) * 1996-03-13 1997-09-19 Merck Sharp Dohme Chibret Lab Composition ophtalmologique du type subissant une transition de phase liquide-gel
FR2754712A1 (fr) * 1996-10-17 1998-04-24 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
WO1998017249A1 (fr) * 1996-10-17 1998-04-30 Laboratoires Merck Sharp & Dohme-Chibret Snc Compositions ophtalmiques contenant un inhibiteur d'anhydrase carbonique et de la gomme de xanthane
US6264935B1 (en) 1996-10-17 2001-07-24 Laboratoires Msd - Chibret Ophthalmic composition containing a carbonic anhydrase inhibitor and xanthan gum
WO1998023292A1 (fr) * 1996-11-29 1998-06-04 Monsanto Company Gel lubrifiant autonome (intact) utile pour apporter par voie orale des ingredients biologiquement actifs
US8889176B2 (en) 2003-01-10 2014-11-18 Depomed, Inc. Method of managing or treating pain
US8216604B2 (en) 2003-01-10 2012-07-10 Archimedes Development Limited Method of managing or treating pain
US9078814B2 (en) 2003-01-10 2015-07-14 Depomed, Inc. Intranasal spray device containing pharmaceutical composition
US9814705B2 (en) 2003-01-10 2017-11-14 Depomed, Inc. Intranasal spray device containing pharmaceutical composition
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US11633350B2 (en) 2014-02-23 2023-04-25 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
US12005089B2 (en) 2014-12-15 2024-06-11 The Johns Hopkins University CVS transplantation for treatment of bacterial vaginosis
US10485757B2 (en) 2015-01-27 2019-11-26 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
US11426345B2 (en) * 2015-01-27 2022-08-30 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
US20230074691A1 (en) * 2015-01-27 2023-03-09 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN109260146A (zh) * 2018-10-12 2019-01-25 广州大光制药有限公司 地夸磷索钠眼用即用型凝胶滴眼液及制备方法

Also Published As

Publication number Publication date
JPH08510731A (ja) 1996-11-12
EP0706372A1 (fr) 1996-04-17
CA2164113A1 (fr) 1994-12-08
SE9301877D0 (sv) 1993-06-02
AU6940594A (en) 1994-12-20

Similar Documents

Publication Publication Date Title
KR940000229B1 (ko) 생리학적 액체와 접촉하여 겔화되는 약제학적 조성물의 제조방법
EP0844868B1 (fr) Composition contenant du O-carboxymethyl-chitosan et utilisation en ophthalmologie
US5106615A (en) Eyedrops having non-newtonian rheological properties
US9216167B2 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
IE69016B1 (en) Nonaqueous fluorinated drug delivery vehicle suspensions
US20100267664A1 (en) Ophthalmic compositions containing polysaccharide-borate gelling system
JP2003506478A (ja) 涙液代替品
EP0706372A1 (fr) Gel a usage therapeutique in situ
FR2660193A1 (fr) Produit opthalmique comportant des nanocapsules, son procede de preparation et utilisation des nanocapsules.
US5200180A (en) Pharmaceutical composition for the treatment of the human eye
EP1189595A1 (fr) Compositions ophthalmiques sous forme de gels aqueux
AU760641B2 (en) Ophthalmic compositions and process of using
JP5041761B2 (ja) 眼粘膜適用製剤
BG64740B1 (bg) Използване на гликогенен полизахарид като активенкомпонент за получавaнe на очен разтвор
JPS63502270A (ja) 散瞳作用を有する眼科用医薬組成物
JP2003267892A (ja) 熱ゲル化人工涙液

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2164113

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994917868

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1996 564131

Country of ref document: US

Date of ref document: 19960327

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1994917868

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994917868

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载